julian hurdle

Employment

Employment history is unavailable.

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (61)

• An integrated view of metabolic and physiological regulation of toxin production in Clostridioides difficile
  Journal of Bacteriology 2026 DOI: 10.1128/jb.00318-26
  +Save
• Case Commentary: Emergence of clinically relevant fidaxomicin-resistant Clostridioides difficile strains
  Antimicrobial Agents and Chemotherapy 2026 DOI: 10.1128/aac.00482-26
  +Save
• Development of a high-throughput screening platform for C. difficile toxin synthesis inhibitors unveils meclizine as an antivirulence agent
  Antimicrobial Agents and Chemotherapy 2026 DOI: 10.1128/aac.00960-25
  +Save
• The microbiome-restorative potential of ibezapolstat for the treatment of Clostridioides difficile infection is predicted through variant PolC-type DNA polymerase III in Lachnospiraceae and Oscillospiraceae
  Jacob K. McPherson, Julian Gregston Hurdle, Matthew L. Baker +3 more
  Antimicrobial Agents and Chemotherapy 2025 DOI: 10.1128/aac.01679-24
  +Save
• Fidaxomicin resistance in Clostridioides difficile : a systematic review and predictive modeling with RNA polymerase binding sites
  Antimicrobial Agents and Chemotherapy 2024 DOI: 10.1128/aac.01206-24
  +Save
• Chemical genetic analysis of enoxolone inhibition of Clostridioides difficile toxin production reveals adenine deaminase and ATP synthase as antivirulence targets
  Journal of Biological Chemistry 2024 DOI: 10.1016/j.jbc.2024.107839
  +Save
• Reduced Vancomycin Susceptibility in Clostridioides difficile Is Associated With Specific Ribotypes
  Open Forum Infectious Diseases 2024 DOI: 10.1093/ofid/ofae588
  +Save
• Evaluation of Fusobacterium nucleatum Enoyl-ACP Reductase (FabK) as a Narrow-Spectrum Drug Target
  ACS Infectious Diseases 2024 DOI: 10.1021/acsinfecdis.3c00710
  +Save
• In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy
  Antimicrobial Agents and Chemotherapy 2024 DOI: 10.1128/aac.01222-23
  +Save
• In vivoevaluation ofClostridioides difficileenoyl-ACP reductase II (FabK) Inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy
  2023 DOI: 10.1101/2023.09.22.559005
  +Save
• The licorice metabolite enoxolone attenuates Clostridioides difficile pathophysiology by corrupting its metabolic and toxin production networks
  2022 DOI: 10.1101/2022.04.20.488993
  +Save
• The Ferrous Iron Transporter FeoB1 is Essential for Clostridioides difficile Toxin Production and Pathogenesis in Mice
  2022 DOI: 10.1101/2022.03.03.482942
  +Save
• Ebselen Not Only Inhibits Clostridioides difficile Toxins but Displays Redox-Associated Cellular Killing
  Microbiology Spectrum 2021 DOI: 10.1128/Spectrum.00448-21
  +Save
• The Integrity of Heme Is Essential for Reproducible Detection of Metronidazole-Resistant Clostridioides difficile by Agar Dilution Susceptibility Tests
  Journal of Clinical Microbiology 2021 DOI: 10.1128/JCM.00585-21
  +Save
• Systems biology evaluation of refractory Clostridioides difficile infection including multiple failures of fecal microbiota transplantation
  Anaerobe 2021 DOI: 10.1016/j.anaerobe.2021.102387
  +Save
• Chromosomal resistance to metronidazole in Clostridioides difficile can be mediated by epistasis between iron homeostasis and oxidoreductases
  bioRxiv 2020 DOI: 10.1101/2020.03.04.977868
  +Save
• Constitutive expression of the cryptic vanG<inf>Cd</inf> operon promotes vancomycin resistance in Clostridioides difficile clinical isolates
  Journal of Antimicrobial Chemotherapy 2020 DOI: 10.1093/jac/dkz513
  +Save
• Ebselen exhibits antimicrobial activity against clostridioides difficile by disrupting redox associated metabolism
  bioRxiv 2020 DOI: 10.1101/2020.07.27.224337
  +Save
• The early stage peptidoglycan biosynthesis Mur enzymes are antibacterial and antisporulation drug targets for recurrent Clostridioides difficile infection
  Anaerobe 2020 DOI: 10.1016/j.anaerobe.2019.102129
  +Save
• Small-Molecule Inhibition of the C. difficile FAS-II Enzyme, FabK, Results in Selective Activity
  ACS Chemical Biology 2019 DOI: 10.1021/acschembio.9b00293
  +Save